Sirna to Manufacture Archemix Drug Candidate
Sirna Therapeutics has signed on to manufacture for Archemix the antithrombin aptamer ARC183, the companies said this week.
ARC183 is Archemix’s first drug development candidate and is being tested for use as an anti- coagulant/anti-thrombotic in coronary artery bypass graft surgery. Under the arrangement, Sirna will make and supply Archemix with the agent for use in its development efforts through phase IIa clinical trials.
Specific terms of the deal were not disclosed.